These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7006709)

  • 21. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1).
    Greipp PR; Witzig TE; Gonchoroff NJ
    Am J Hematol; 1985 Nov; 20(3):289-92. PubMed ID: 3904417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
    Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen induced expansion of the growth fraction in receptor negative human breast cancer.
    Conte PF; Fraschini G; Drewinko B
    J Steroid Biochem; 1985 Dec; 23(6B):1169-72. PubMed ID: 4094431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy for multiple myeloma.
    Alexanian R; Dreicer R
    Cancer; 1984 Feb; 53(3):583-8. PubMed ID: 6362819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses.
    Omedè P; Tarella C; Palumbo A; Argentino C; Caracciolo D; Corradini P; Dominietto A; Giaretta F; Ravaglia R; Triolo R; Triolo S; Pileri A; Boccadoro M
    Br J Haematol; 1997 Dec; 99(3):685-91. PubMed ID: 9401085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermittent high-dose cyclophosphamide chemotherapy for small cell carcinoma of the lung.
    Ettinger DS; Karp JE; Abeloff MD; Burke PJ; Braine HG
    Cancer Treat Rep; 1978 Mar; 62(3):413-24. PubMed ID: 348309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VAD followed by VMCP: an alternative regimen for multiple myeloma.
    Wadhwa J; Kumar L; Kochupillai V
    Med Oncol; 2002; 19(2):105-8. PubMed ID: 12180477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
    Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D
    Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination chemotherapy for metastatic breast cancer: comparison of multiple drug therapy with 5-fluorouracil, cytoxan and prednisone with adriamycin or adrenalectomy.
    Nemoto T; Rosner D; Diaz R; Dao T; Sponzo R; Cunningham T; Horton J; Simon R
    Cancer; 1978 Jun; 41(6):2073-7. PubMed ID: 657080
    [No Abstract]   [Full Text] [Related]  

  • 31. Modern treatments and future directions for newly diagnosed multiple myeloma patients.
    Lu SX
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101151. PubMed ID: 32139016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
    Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VAD chemotherapy for refractory multiple myeloma.
    Lokhorst HM; Meuwissen OJ; Bast EJ; Dekker AW
    Br J Haematol; 1989 Jan; 71(1):25-30. PubMed ID: 2644970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
    Barlogie B; Smith L; Alexanian R
    N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-paraprotein producing myeloma.
    McLaughlin H; Farrelly PA; Melinn M
    Ir J Med Sci; 1976 May; 145(5):181-3. PubMed ID: 1017926
    [No Abstract]   [Full Text] [Related]  

  • 36. Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-B-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia.
    Karp JE; Donehower RC; Dole GB; Burke PJ
    Blood; 1987 Apr; 69(4):1134-40. PubMed ID: 3470054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Belch A; Skillings J; Wilson K; Bergsagel D; Johnston D; Pater JL
    Br J Haematol; 1992 Nov; 82(3):555-9. PubMed ID: 1486035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of human myeloma cell population kinetics.
    Montecucco C; Riccardi A; Ucci G; Danova M; Carnevale R; Caporali R; Longhi M; Luoni R
    Acta Haematol; 1986; 75(3):153-6. PubMed ID: 3092531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years].
    Bataille R; Morlock G; Rosenberg F; Lopitaux R; Blotman F; Sany J; Ciurana AJ; Rampon S; Bussière JL; Simon L; Serre H
    Rev Rhum Mal Osteoartic; 1980 Feb; 47(2):77-82. PubMed ID: 7361063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.
    Oakman C; Francis PA; Crown J; Quinaux E; Buyse M; De Azambuja E; Margeli Vila M; Andersson M; Nordenskjöld B; Jakesz R; Thürlimann B; Gutiérrez J; Harvey V; Punzalan L; Dell'orto P; Larsimont D; Steinberg I; Gelber RD; Piccart-Gebhart M; Viale G; Di Leo A
    Ann Oncol; 2013 May; 24(5):1203-11. PubMed ID: 23293111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.